New combo therapy may let CML patients pause treatment again

NCT ID NCT03610971

First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 30 times

Summary

This study tests whether adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) therapy helps people with chronic myeloid leukemia (CML) stay in remission after stopping their medication. It includes 24 adults who previously tried and failed to stop TKI therapy. Participants receive the combination for 12 cycles, then attempt to stop all treatment, with the goal of achieving long-term drug-free remission.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PHASE CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering

    New York, New York, 10021, United States

  • Duke University Hospital

    Durham, North Carolina, 27710, United States

  • Emory -Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • Froedtert Hospital & the Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612, United States

  • Memorial Sloan Kettering - Bergen

    Montvale, New Jersey, 07645, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14263, United States

Conditions

Explore the condition pages connected to this study.